Clinical Guides
Alopecia and Hair Loss
A clinically focused clinical guide to patterned, patchy, diffuse and scarring hair loss, integrating morphology, targeted investigation, reproductive safety, minoxidil, systemic and immune therapy, irreversible follicular-loss warnings, psychosocial care and Indian access constraints.
MedNext Academy | 13 min read
Alopecia and Hair Loss
A clinically focused clinical guide to patterned, patchy, diffuse and scarring hair loss, integrating morphology, targeted investigation, reproductive safety, minoxidil, systemic and immune therapy, irreversible follicular-loss warnings, psychosocial care and Indian access constraints.
Summary
Alopecia means hair loss; it is a clinical description, not a single diagnosis. The first decision is whether follicular openings are preserved. Non-scarring disorders, including androgenetic alopecia, alopecia areata and telogen effluvium, retain potential for regrowth. Cicatricial disorders destroy follicles, making delay important because lost hair cannot reliably return. Pattern, tempo, symptoms, broken hairs, scalp inflammation and involvement of eyebrows, eyelashes, nails or body hair then narrow the cause.
History and scalp examination usually establish a working diagnosis. Trichoscopy improves morphological assessment when available. Tests are targeted to clues such as diffuse shedding, nutritional restriction, menstrual disturbance, virilisation, systemic illness, autoimmune disease or infection. A pull test samples active shedding but is neither disease-specific nor a substitute for examining the scalp. Biopsy is considered when scarring alopecia, an inflammatory border or diagnostic uncertainty remains.
Treatment must match the disorder. Topical minoxidil can support patterned hair loss and sometimes density in other conditions, but requires sustained use and reproductive and cardiovascular safety review. Finasteride is relevant to selected male-pattern disease, not all alopecia. Alopecia areata may require corticosteroid, contact-immunotherapy, conventional systemic or Janus kinase inhibitor pathways under dermatology supervision. Active scarring alopecia needs early anti-inflammatory treatment to preserve remaining follicles. Camouflage, hairpieces and psychological support are legitimate care. This educational draft remains reviewed and has been reviewed by the MedNext Clinical Team.
How Common Is It?
Hair loss is frequent across the lifespan, but its frequency depends on the phenotype and the population sampled. Androgenetic alopecia becomes more common with age and may begin after puberty. Alopecia areata can arise in children or adults and ranges from one small patch to loss of the entire scalp or body. Telogen effluvium often follows a physiological or psychological stressor, while cicatricial alopecias are individually less common but disproportionately important because damage may be permanent.
A single Indian prevalence percentage would be misleading. Studies vary in diagnostic criteria, age structure, sex distribution, ethnicity, urban access and whether they count self-reported shedding or dermatologist-confirmed disease. Clinic series also overrepresent severe, persistent and treatment-resistant cases. Hair practices and visibility differ across hair texture and skin colour; inflammation or erythema may be underestimated if assessment relies on colour alone.
Clinical burden is not measured by scalp area only. Eyebrow or eyelash loss, rapid change, visible patches, occupational exposure and cultural or religious meaning can produce major functional and psychosocial effects. Alopecia areata severity assessments may incorporate scalp extent, facial-hair involvement, rapid progression, treatment failure and psychological impact. Conversely, a common patterned thinning can be medically uncomplicated yet deeply distressing. Record the patient's own goals rather than assuming the condition is merely cosmetic. Local service planning should track diagnosis, scarring status, waiting time, treatment monitoring and access to pathology rather than advertise an unverified national rate.
Risk Factors
Family history and androgen sensitivity are central to androgenetic alopecia. Earlier onset can predict a longer period of progression, but family history may be absent or unclear. Alopecia areata reflects autoimmune susceptibility and is associated with other immune-mediated disorders, including thyroid disease, vitiligo and type 1 diabetes, without justifying indiscriminate screening in every patient. Scarring alopecias encompass immune, infectious, traumatic and inflammatory processes; lichen planopilaris and discoid lupus are important examples.
Diffuse shedding may follow fever, surgery, childbirth, marked weight change, restrictive diets, iron deficiency, thyroid disturbance, severe stress or a new medicine. The interval between trigger and shedding matters because telogen release is delayed. Cytotoxic treatment can produce anagen effluvium with a different tempo. Tight braids, extensions, repeated heat, chemical straightening and chronic tension can cause traction alopecia; early disease can recover, whereas longstanding traction may scar. Tinea capitis risk is influenced by age and close contact and requires microbiological assessment.
Ask about anticoagulants, retinoids, antithyroid drugs, anticonvulsants, beta blockers and other temporally related medicines without implying causation or stopping essential therapy abruptly. Hyperandrogenism clues include irregular menses, hirsutism, acne, infertility or virilisation. Pregnancy, pregnancy intention and breastfeeding alter safe treatment. Smoking and ultraviolet exposure can worsen particular inflammatory scalp disorders. Hair loss also increases vulnerability to unregulated supplements, compounded solutions and commercial procedures. Product contamination, excessive vitamin or mineral dosing and delayed diagnosis are avoidable harms; request packages, prescriptions and photographs before accepting a treatment history as complete.
Diagnosis
History
Define onset, speed, shedding versus thinning, distribution and previous episodes. Ask about itch, pain, burning, scale, pustules, crust, broken hairs and loss at other sites. Establish illness, childbirth, weight change, nutrition, menstrual and androgen symptoms, autoimmune disease, infection exposure, hair practices, medicines and family pattern. Document pregnancy plans and emotional effect, including avoidance, bullying, depression or self-harm. Clarify every previous treatment, duration, adherence, benefit and adverse effect.
Examination
Inspect the entire scalp in good light, comparing density and shaft calibre across frontal, temporal, vertex, occipital and marginal zones. Decide whether follicular openings remain. Look for miniaturisation, exclamation-mark hairs, black dots, yellow dots, perifollicular scale, erythema, shiny atrophy, tufting, pustules, lymphadenopathy and traction signs. Perform a gentle hair-pull test at multiple sites when active shedding is suspected. Examine eyebrows, eyelashes, body hair, nails, oral or cutaneous lichen planus, lupus lesions and signs of androgen excess with consent. Trichoscopy should document, not replace, clinical reasoning.
Investigations
Do not order a universal hair-loss panel. CBC and ferritin, thyroid testing, renal or liver studies, vitamin assessment, inflammatory tests or androgen evaluation are selected by history and examination. Obtain fungal microscopy and culture when tinea is plausible; avoid corticosteroid monotherapy before excluding infection. Photograph consistent views for progression. A scalp biopsy from an active inflammatory margin, with orientation and clinicopathological question communicated to pathology, is valuable for suspected scarring disease or unresolved diagnosis. Histology can classify a process but may not identify a late burnt-out scar.
Differential Diagnosis
Patterned frontotemporal and vertex miniaturisation in men, or widening central part with preserved frontal margin in many women, supports androgenetic alopecia. Diffuse shedding with preserved scalp surface suggests telogen effluvium, but chronic shedding may coexist with patterned loss. Abrupt smooth patches, exclamation-mark hairs, nail pitting or eyebrow involvement favour alopecia areata. Trichotillomania produces irregular patches and hairs of different lengths; diagnosis requires non-judgmental assessment rather than confrontation. Traction follows the geography of sustained pulling and may show a retained fringe early.
Scale, broken hairs, black dots, pustules or lymph nodes raise tinea capitis; inflammatory kerion requires prompt treatment to limit scarring. Seborrhoeic dermatitis and psoriasis cause scale but usually do not by themselves explain sharply reduced follicular density. Syphilis, lupus, secondary endocrine disease, nutritional deficiency and drug-related shedding are considered from context rather than screened indiscriminately. Postpartum shedding is usually telogen effluvium, while progressive widening may reveal pre-existing patterned loss.
Loss of follicular openings, perifollicular scale, erythema, burning, tenderness, eyebrow recession or smooth pale areas suggests scarring alopecia. Lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, discoid lupus, folliculitis decalvans and dissecting cellulitis require distinction because treatment and infection considerations differ. Tumour, radiation, pressure and burn scars are alternative causes. A smooth old scar is not evidence that inflammation is still active; conversely, a narrow active border can advance despite little shedding. Biopsy timing and site selection therefore matter.
Management
Begin by naming the working diagnosis, uncertainty and whether loss is currently reversible. Correct a documented trigger or deficiency, modify damaging traction and treat scalp infection or inflammation. Gentle hair care, sun protection for exposed scalp and realistic photographs support follow-up. Shaving does not thicken follicles. Biotin should not be prescribed automatically; high intake may interfere with laboratory assays. Cosmetic fibres, scarves, wigs and hairpieces can improve function and confidence and should not be dismissed while medical treatment proceeds.
For androgenetic alopecia, topical minoxidil is a common evidence-based option when formulation, contraindications and expectations are appropriate. Benefit takes months, initial shedding or irritation can occur, and gains recede after stopping. Finasteride can slow male-pattern loss in selected adults after sexual, reproductive and psychiatric safety counselling. Low-dose oral minoxidil, dutasteride, antiandrogens, platelet-rich plasma, microneedling and light devices have varying evidence, licensing and monitoring requirements; none should be marketed as a guaranteed upgrade. Hair transplantation is considered only after diagnosis and disease stability, particularly avoiding active scarring disease.
Limited alopecia areata may be observed or treated with local corticosteroid approaches; extent, age, site and psychosocial impact guide escalation. Contact immunotherapy, systemic corticosteroids, conventional immunomodulators or licensed JAK inhibitors are specialist options with infection, thrombotic, malignant, reproductive and laboratory considerations. Scarring alopecia treatment targets inflammation with topical, intralesional or systemic therapy; regrowth cannot be promised once follicles are destroyed. Treatment goals, stop rules and reassessment measures must be documented.
Prescribing Information
Topical minoxidil should be applied to intact scalp according to the locally authorised product, not improvised from a percentage alone. Counsel about irritation, unwanted facial hair, early shedding, delayed benefit and loss of effect after cessation. Excess use does not accelerate growth. Palpitations, chest pain, syncope, oedema or significant dizziness require cessation and medical assessment. Oral minoxidil for hair loss is off-label in many jurisdictions and needs clinician-led blood-pressure, pulse, cardiovascular, interaction and pregnancy review; it is not simply a stronger topical product. Both topical and oral minoxidil should be avoided in pregnancy under the cited alopecia areata guidance.
Finasteride is diagnosis- and patient-specific. Discuss sexual adverse effects and psychiatric warnings, baseline fertility concerns where relevant, and the fact that response requires continued therapy. It is contraindicated in pregnancy because inhibition of dihydrotestosterone can harm development of a male fetus; pregnant people should not handle crushed or broken tablets. Dutasteride has a longer half-life and is not an interchangeable routine choice. Antiandrogens used in women require reliable pregnancy prevention and monitoring appropriate to the drug.
Intralesional or potent topical corticosteroids can cause atrophy, telangiectasia, dyspigmentation or systemic effects if misused. Systemic corticosteroids risk metabolic, bone, infection and psychiatric toxicity and relapse after withdrawal. Methotrexate and mycophenolate are teratogenic; JAK inhibitors are avoided in pregnancy and require serious-infection and other risk assessment; ciclosporin needs blood-pressure and renal monitoring. Hydroxychloroquine requires dose and retinal-safety planning. Exact selection, dose and monitoring must follow current Indian product information and dermatology protocols.
When to Refer
Refer urgently to dermatology when examination suggests active scarring alopecia: disappearing follicular openings, perifollicular scale or erythema, smooth shiny patches, rapidly receding frontal margin, eyebrow loss, scalp pain or burning. The purpose is to preserve follicles that remain, not to promise replacement of hair already destroyed. Inflammatory tinea with boggy swelling, pus, systemic illness or threatened scarring also needs prompt clinician assessment and systemic antifungal planning.
Early specialist review is appropriate for rapid unexplained loss, extensive alopecia areata, eyelash or eyebrow involvement, paediatric disease, diagnostic uncertainty, virilisation, suspected systemic autoimmune disease, treatment failure or a need for biopsy. Refer where potent systemic, immunomodulatory, JAK-inhibitor, antiandrogen or oral-minoxidil therapy is being considered and local competence or monitoring is insufficient. Pregnancy or preconception planning while taking a potentially teratogenic medicine requires coordinated dermatology and obstetric or physician advice rather than abrupt unsupervised changes.
Psychological referral is indicated when distress is severe, functioning deteriorates or there is suicidal thinking; this is clinical urgency even if scalp disease is stable. Endocrinology or gynaecology assessment follows significant androgen-excess features, not hair thinning alone. Paediatric, infectious-disease or rheumatology input is selected by cause. A useful referral includes onset, progression images, scarring assessment, relevant systemic features, hair practices, medicines, tests already performed, pregnancy status, treatments with duration and the patient's main goal. Continue safe supportive measures while waiting and state what change should trigger escalation.
Red Flags
The central hair-specific red flag is threatened permanent follicular destruction. Loss of openings, a smooth shiny surface, perifollicular scale or erythema, tufted hairs, pustules, crust, expanding margin, disproportionate itch, tenderness or burning should not be managed as ordinary patterned thinning. Rapid eyebrow and frontotemporal recession may signal frontal fibrosing alopecia. A boggy tender plaque, purulent discharge, fever or lymphadenopathy suggests inflammatory infection or abscess and needs urgent evaluation.
Sudden diffuse loss accompanied by weight loss, fever, severe dietary restriction, bleeding, endocrine symptoms or systemic illness requires broader assessment. Virilisation, deepening voice, clitoromegaly or rapidly progressive hirsutism is more concerning than isolated long-standing acne. Moth-eaten loss with sexual-risk history, rash or neurological symptoms requires appropriate infection testing. A fixed ulcerated, bleeding or nodular scalp lesion needs malignancy exclusion rather than repeated hair-growth products.
Medicine red flags include pregnancy exposure to finasteride, dutasteride, methotrexate, mycophenolate, retinoids or a JAK inhibitor; syncope, chest pain, oedema or tachycardia with minoxidil; serious infection on immune therapy; and marked mood change or suicidal ideation. These require prompt clinical action appropriate to the exposure, not online reassurance. Severe appearance-related distress, school refusal, social withdrawal or self-harm thoughts must be asked about directly and escalated. Counterfeit tablets, unlabeled injections and compounded mixtures with hidden corticosteroid or antiandrogen are safety concerns even when photographs appear improved.
Indian Clinical Context
Hair-loss care in India spans government dermatology clinics, private practices, pharmacies, salons, transplant centres and direct-to-consumer platforms. Access to trichoscopy, fungal culture, dermatopathology and immune-therapy monitoring is uneven. A safe plan must remain workable if follow-up, laboratory testing or cold-chain supply is uncertain. Generic name, formulation, actual cost and review interval should be written clearly; a commercial package or procedure bundle is not a diagnosis.
Patients may have used hair oils, herbal preparations, nutritional powders, topical steroid combinations, salon procedures, mesotherapy or online finasteride-minoxidil mixtures before presentation. Ask neutrally and inspect labels. Traditional hair practices are culturally meaningful; advise on tension, heat and chemical damage without blaming identity or demanding a hairstyle that is impractical. Scalp erythema can be subtle in richly pigmented skin, while post-inflammatory pigment change may be prominent. Fungal disease, traction and central scarring patterns require deliberate inspection.
India-specific prescribing must follow current CDSCO-authorised information, local formularies and specialist protocols. International BAD guidance informs principles but does not establish Indian funding, licensing or availability for JAK inhibitors, contact immunotherapy or low-dose oral minoxidil. Teratogenicity counselling must be private, respectful and not based on marital status. Hair transplantation and platelet-rich plasma advertising often exceeds evidence; document diagnosis, stability, donor limitations, complications and financial consent. The minimum equitable package is correct scarring triage, source-grounded counselling, affordable supportive care, a safety net and referral when monitoring cannot be delivered locally.
NMC Competency Mapping
The NMC Competency Based Medical Education Curriculum 2024 does not provide a clearly named standalone undergraduate alopecia competency in the dermatology table. Formal mapping should therefore be transparent and should not invent a DR code. Hair loss supports broader outcomes in dermatological history, morphology, differential diagnosis, rational investigation, therapeutics, referral and communication, with integration across anatomy of skin appendages, pathology, microbiology, pharmacology, medicine, paediatrics, obstetrics and psychiatry.
A graduating learner should distinguish scarring from non-scarring loss, describe patterned, patchy and diffuse distributions, examine follicular openings and recognise inflammatory borders. They should take trigger, medicine, nutrition, reproductive, autoimmune, infection, hair-care and psychological histories. Investigation competence means choosing tests from clues, obtaining fungal samples correctly and explaining when trichoscopy or biopsy changes management. Students should recognise alopecia areata, tinea capitis, androgenetic alopecia, telogen effluvium, traction alopecia and dangerous scarring patterns without claiming specialist certification.
Therapeutic learning includes accurate minoxidil counselling, limits of finasteride, avoidance of teratogenic exposure, local corticosteroid principles, the monitored nature of systemic immune therapy and referral for irreversible disease. Assessment can use a scalp-description station, diagnostic comparison, reproductive-safety prescription critique and scarring-red-flag vignette. Competence is demonstrated by safe reasoning and honest uncertainty, not by memorising a commercial transplant scale or claiming every shedding complaint requires ferritin, thyroid, vitamin D and hormone panels. This guide supplements supervised clinical teaching and remains unapproved until organizational review.
Key Exam Pearls for NEET PG
Start every alopecia answer with scarring versus non-scarring. Preserved follicular openings imply potentially reversible non-scarring disease; absent openings and shiny atrophy imply follicular destruction. Alopecia areata classically gives smooth patches, exclamation-mark hairs and sometimes nail pitting. Androgenetic alopecia shows patterned miniaturisation. Telogen effluvium produces diffuse shedding after a delayed trigger. Tinea capitis gives scale and broken hairs and needs systemic antifungal treatment, while traction follows sustained mechanical tension.
In Diagnosis, write History, Examination and Investigations. History must include tempo, symptoms, triggers, medicines, diet, hair practices, pregnancy and systemic disease. Examination includes the whole scalp, hair shafts, follicular openings, pull test when indicated, nails and other hair-bearing sites. Investigations are selective; biopsy an active border when scarring disease is suspected. Late scar tissue may be nondiagnostic and cannot be made to regrow by minoxidil.
Minoxidil requires months and continued use; early shedding and dermatitis can occur. Oral minoxidil is not a routine unsupervised escalation. Finasteride reduces dihydrotestosterone in selected male-pattern disease and is contraindicated in pregnancy. Alopecia areata therapy escalates from observation or local corticosteroid approaches to specialist contact or systemic immune treatments according to extent and burden. JAK inhibitors require risk screening and do not erase long-term evidence uncertainty.
Exam safety points score highly: painful inflamed scarring margins need early referral; kerion threatens scar; virilisation needs endocrine evaluation; immune drugs and antiandrogens require pregnancy and monitoring safeguards; psychological harm is part of severity. State that treatment preserves remaining follicles in cicatricial alopecia and cannot guarantee regrowth where follicles are destroyed.
Frequently Asked Questions
How can a clinician tell whether hair loss is scarring or non-scarring?
Examine for follicular openings across the affected scalp. Preserved openings, miniaturised or broken hairs and a non-shiny surface support a non-scarring process. Smooth pale or shiny areas with lost openings, perifollicular scale, erythema, tufting, pain or burning suggest cicatricial disease. Trichoscopy can strengthen the assessment, and biopsy from an active margin may be needed. Suspected active scarring alopecia merits early dermatology referral because destroyed follicles do not reliably regrow.
Does minoxidil cure hair loss, and is oral minoxidil simply more effective?
No. Minoxidil can improve density in appropriate diagnoses, particularly patterned hair loss, but it does not cure the underlying tendency and gains usually diminish after stopping. Topical treatment can irritate the scalp and cause early shedding or unwanted facial hair. Oral use is off-label in many settings and adds blood-pressure, pulse, fluid-retention and cardiovascular considerations. Neither formulation should be started in pregnancy, and oral treatment requires clinician selection and monitoring rather than being treated as a stronger cosmetic product.
Which hair-loss medicines are unsafe around pregnancy or conception?
Risk depends on the drug and exposure. Finasteride and dutasteride must not be used during pregnancy because of fetal risk; methotrexate and mycophenolate are teratogenic; retinoids have strict pregnancy-prevention requirements; and current guidance avoids JAK inhibitors and minoxidil in pregnancy. Several antiandrogens also require reliable contraception. A person taking one of these medicines who is pregnant or planning conception should contact the prescriber promptly for drug-specific advice rather than stopping or continuing on internet guidance alone.
When does a patch of hair loss require urgent specialist assessment?
Urgent assessment is appropriate when follicular openings are disappearing, the scalp is painful or burning, an inflammatory edge is advancing, pustules or a boggy swelling suggest infection, or loss involves eyelashes with ocular symptoms. Rapid extensive alopecia, a suspicious ulcer or nodule, virilisation, systemic illness, serious medicine toxicity and severe psychological distress also change urgency. A stable smooth alopecia-areata patch is different, but diagnostic uncertainty and paediatric disease still justify timely review and a clear safety net.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic